CA2835771C - Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration - Google Patents

Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration Download PDF

Info

Publication number
CA2835771C
CA2835771C CA2835771A CA2835771A CA2835771C CA 2835771 C CA2835771 C CA 2835771C CA 2835771 A CA2835771 A CA 2835771A CA 2835771 A CA2835771 A CA 2835771A CA 2835771 C CA2835771 C CA 2835771C
Authority
CA
Canada
Prior art keywords
antiarrhythmic
pharmaceutical agent
minutes
antiarrhythmic pharmaceutical
class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2835771A
Other languages
English (en)
French (fr)
Other versions
CA2835771A1 (en
Inventor
Carlos A. Schuler
Rangachari Narasimhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incarda Therapeutics Inc
Original Assignee
Incarda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incarda Therapeutics Inc filed Critical Incarda Therapeutics Inc
Publication of CA2835771A1 publication Critical patent/CA2835771A1/en
Application granted granted Critical
Publication of CA2835771C publication Critical patent/CA2835771C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2835771A 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration Active CA2835771C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21038209P 2009-03-18 2009-03-18
US61/210,382 2009-03-18
CA2755809A CA2755809C (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2755809A Division CA2755809C (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Publications (2)

Publication Number Publication Date
CA2835771A1 CA2835771A1 (en) 2010-09-23
CA2835771C true CA2835771C (en) 2017-01-24

Family

ID=42739985

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2835771A Active CA2835771C (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CA2755809A Active CA2755809C (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2755809A Active CA2755809C (en) 2009-03-18 2010-03-18 Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Country Status (9)

Country Link
US (5) US8974828B2 (OSRAM)
EP (3) EP3552603B1 (OSRAM)
JP (5) JP2012520890A (OSRAM)
AU (1) AU2010226613B2 (OSRAM)
CA (2) CA2835771C (OSRAM)
DK (1) DK2413902T3 (OSRAM)
ES (3) ES3036464T3 (OSRAM)
PL (1) PL2413902T3 (OSRAM)
WO (1) WO2010107964A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3834869B1 (en) 2010-12-22 2024-06-05 Syqe Medical Ltd. System for drug delivery
US9713687B2 (en) 2012-08-21 2017-07-25 Philip Morris Usa Inc. Ventilator aerosol delivery system with transition adapter for introducing carrier gas
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
TWI590837B (zh) * 2014-03-25 2017-07-11 林信湧 一種用於治療心臟病之吸入式醫藥組成物及其備製方法
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
ES2786318T3 (es) 2014-06-30 2020-10-09 Syqe Medical Ltd Dispositivo inhalador regulador de flujo
ES2898173T3 (es) * 2014-06-30 2022-03-04 Syqe Medical Ltd Dispositivos y sistemas para la administración pulmonar de principios activos
WO2016118625A1 (en) * 2015-01-20 2016-07-28 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
MA52480A (fr) * 2015-04-14 2022-03-09 Milestone Pharmaceuticals Inc Sels hautement solubles dans l'eau d'un agent bloquant les canaux calciques à base de phénylalkylamine à brève durée d'action et leurs utilisations
EP3851102B1 (en) 2016-01-06 2025-04-16 Syqe Medical Ltd. Low dose therapeutic treatment
CN109069495A (zh) 2016-02-01 2018-12-21 英凯达治疗公司 电子监测联合吸入药理学疗法管理包括心房颤动在内的心律失常
CN110869018A (zh) * 2017-05-10 2020-03-06 英凯达治疗公司 通过肺部施用治疗心脏病况的单位剂量、气雾剂、试剂盒和方法
WO2019183470A2 (en) * 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
JP2021526900A (ja) * 2018-06-05 2021-10-11 インカーダ セラピューティクス， インコーポレイテッド エアロゾルを用いるブルガダ症候群の診断方法
EP3806839B1 (en) * 2018-06-14 2024-08-07 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Retinoic acid receptor-beta2 agonist with cardioprotective effects
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
JP7190077B2 (ja) * 2019-08-01 2022-12-14 インカーダ セラピューティクス， インコーポレイテッド 抗不整脈製剤
CA3200432A1 (en) 2020-12-17 2022-06-23 Incarda Therapeutics, Inc. Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
SE408265B (sv) 1975-12-12 1979-06-05 Draco Ab Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (it) 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
JP3202705B2 (ja) * 1987-11-06 2001-08-27 リサーチ ディベロップメント ファンデーション 医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子
US4962095A (en) * 1989-02-15 1990-10-09 E. R. Squibb & Sons, Inc. Method of reducing pre-and post-ischemic myocardial arrhythmias and fibrillation
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
JPH10501519A (ja) 1994-03-07 1998-02-10 インヘイル・セラピューティック・システムズ インシュリンを肺に送給できる方法および組成物
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CA2190502A1 (en) 1994-05-18 1995-11-23 Robert M. Platz Methods and compositions for the dry powder formulation of interferons
JP3388896B2 (ja) 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
EP0820277B1 (en) 1995-04-14 2005-01-26 Nektar Therapeutics Powdered pharmaceutical formulations having improved dispersibility
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6001336A (en) 1996-12-31 1999-12-14 Inhale Therapeutic Systems Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof
WO1999016421A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
CZ20011581A3 (cs) 1998-11-12 2001-12-12 Frank G. Pilkiewicz Systém pro podávání bioaktivní sloučeniny inhalací
ATE331544T1 (de) 1999-05-28 2006-07-15 Nektar Therapeutics Gerät und verfahren zur aerosolisierung einer pharmazeutischen pulverzusammensetzung
AU782841B2 (en) * 2000-04-17 2005-09-01 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US6357490B1 (en) 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
AU2002245181B2 (en) 2000-12-21 2006-06-29 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
WO2002080859A2 (en) 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US20080038363A1 (en) * 2001-05-24 2008-02-14 Zaffaroni Alejandro C Aerosol delivery system and uses thereof
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6737042B2 (en) * 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7090830B2 (en) * 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
AU2002340083A1 (en) * 2001-09-28 2003-04-07 Kurve Technology, Inc Nasal nebulizer
RU2332220C2 (ru) * 2002-04-18 2008-08-27 Си Ви Терапьютикс, Инк. Способ снижения частоты сердечных сокращений, включающий введение агониста рецептора аденозина а1 вместе с бета-блокатором, блокатором кальциевых каналов или сердечным гликозидом
US8245708B2 (en) 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
CA2485340C (en) 2002-05-07 2015-09-29 The State University Of New York At Stony Brook Methods, devices and formulations for targeted endobronchial therapy
JP2006513236A (ja) 2002-12-31 2006-04-20 ネクター セラピューティクス 不溶性活性物質を伴う医薬製剤
AU2004238217A1 (en) * 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
BRPI0617655A2 (pt) * 2005-10-21 2016-08-23 Merck & Co Inc composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
NZ576637A (en) 2006-10-25 2012-05-25 Novartis Ag Powder dispersion apparatus with and mediciment receptacles that are cut open using an elliptical arc shaped knife blade oriented to yaw between 4 and 12 degrees
WO2008066745A1 (en) * 2006-11-22 2008-06-05 Reliant Pharmaceuticals, Inc. Prophlyaxis and treatment of atrial fibrillation with omega-3 fatty acids
TW200840578A (en) 2006-12-15 2008-10-16 Procter & Gamble Compositions of azimilide dihydrochloride
WO2008134630A1 (en) * 2007-04-30 2008-11-06 Apt Pharmaceuticals Dexrazoxane compounds for cardioprotection
US20080275036A1 (en) * 2007-05-02 2008-11-06 Apt Pharmaceuticals, Inc. Prevention and treatment of cardiac conditions
CA2733930A1 (en) 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods of their identification, and kits therefore
CA2734780C (en) 2008-08-22 2016-07-05 Milestone Pharmaceuticals Inc. Short acting benzothiazepine calcium channel blockers and uses thereof
MX356209B (es) * 2008-09-23 2018-05-18 Laboratory Skin Care Inc Partículas de fosfato de calcio nanoporosas, esféricas, rígidas, uniformes cargadas de agente activo y métodos para su fabricación y su uso.
CA2835771C (en) 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Also Published As

Publication number Publication date
EP2413902A4 (en) 2014-02-19
US8974828B2 (en) 2015-03-10
CA2835771A1 (en) 2010-09-23
CA2755809A1 (en) 2010-09-23
US20190060230A1 (en) 2019-02-28
EP3552602B1 (en) 2025-03-05
DK2413902T3 (da) 2019-10-07
WO2010107964A1 (en) 2010-09-23
JP2019203032A (ja) 2019-11-28
JP7071949B2 (ja) 2022-05-19
CA2755809C (en) 2014-02-18
EP2413902A1 (en) 2012-02-08
JP6715305B2 (ja) 2020-07-01
EP3552603C0 (en) 2024-11-06
US20150313842A1 (en) 2015-11-05
JP2017160268A (ja) 2017-09-14
EP3552603B1 (en) 2024-11-06
US20180318213A1 (en) 2018-11-08
US20120003318A1 (en) 2012-01-05
AU2010226613B2 (en) 2013-07-25
JP2015193657A (ja) 2015-11-05
US20180296480A1 (en) 2018-10-18
PL2413902T3 (pl) 2020-01-31
ES3036464T3 (en) 2025-09-19
EP2413902B1 (en) 2019-07-17
EP3552602C0 (en) 2025-03-05
JP2012520890A (ja) 2012-09-10
AU2010226613A1 (en) 2011-09-29
ES3003038T3 (en) 2025-03-10
EP3552603A1 (en) 2019-10-16
ES2750359T3 (es) 2020-03-25
JP2019019139A (ja) 2019-02-07
US10045939B2 (en) 2018-08-14
EP3552602A1 (en) 2019-10-16

Similar Documents

Publication Publication Date Title
CA2835771C (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US20230092389A1 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2013248242B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2016256776B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013847A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1166952A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1166952B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013847B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131203